Cognizants shift from the boys to mens club got official sanction this
timethe FY10 growth at more than five times the likes of TCS, Infosys and Wipro
(along with HCL Technologies) has finally justified the clubbing of the WITCH
companies under one bracket. What separated Cognizant was how it dared to dream
bigrecession or not, it made more acquisitions in FY10 than what it had done in
the last three years put together. These included Pepperweed Advisors with IT
infrastructure consulting capabilities; Paris based IT testing firm, Galileo
Performance; London based, PIPC Group with global program management skills as
well as UBS India Service Center, the Hyderabad based captive service provider
to the UBS Group.
These acquisitions helped Cognizant to expound on its four-by-four-by-four
strategy, whereby it expanded its circle of offerings, existing service lines
and geographies to four eachthe newer focus areas were retail, telecom and
media, the APAC (including India) market and practices like infrastructure
management services and engineering & manufacturing solutions. Deals inked with
Harris Corporation, Houghton Mifflin Harcourt, Invensys Rail, ELEXON and Rodale
during FY10 proved the success of this strategy.
|
||
|
||
|
Francisco D Souza, CEO
Rajeev Mehta, COO |
HIGHLIGHTS
6
|
FACTSHEET l Start-up Year: |
The EMS practice, the result of its relationship with Invensys, over the year
grew to nearly about 1,000 associates and opened up an entirely new market for
Cognizant in process manufacturing. On the domestic front, Cognizant serviced
Pfizer Global Research and Development (clinical data management and biometric
services), SAP Labs (set up the SAP NetWeaver test center in Bengaluru),
mjunction services (e-commerce infrastructure for this JV between Tata Steel and
SAIL), and interestingly Shri Saibaba Sansthan Trust, Shirdi to provide
integrated SI services.
The company also harped on its Two-in-a-Box client engagement model as its
key value proposition. The Sanofi Pasteur deal in which Cognizant was selected
as its global partner for clinical trials data management was cited as a
successful proof point of this model.